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Abstract
Aims/hypothesis An association between elevated fasting
plasma glucose and the common rs560887 G allele in the
G6PC2/ABCB11 locus has been reported. In Danes we
aimed to examine rs560887 in relation to plasma glucose
and serum insulin responses following oral and i.v. glucose
loads and in relation to hepatic glucose production during a
hyperinsulinaemic–euglycaemic clamp. Furthermore, we
examined rs560887 for association with impaired fasting
glycaemia (IFG), impaired glucose tolerance (IGT), type 2
diabetes and components of the metabolic syndrome.
Methods rs560887 was genotyped in the Inter99 cohort
(n=5,899), in 366 young, healthy Danes, in non-diabetic
relatives of type 2 diabetic patients (n=196), and in young
and elderly twins (n=159). Participants underwent an
OGTT, an IVGTT or a 2 h hyperinsulinaemic–euglycaemic
clamp.
Results The rs560887 G allele associated with elevated fasting
plasma glucose (p=2×10−14) but not with plasma glucose
levels at 30 min (p=0.9) or 120 min (p=0.9) during an OGTT.
G allele carriers had elevated levels of serum insulin at 30 min
during an OGTT (p=1×10−4) and relatives of type 2 diabetes
patients carrying the G allele had an increased acute insulin
response (p=4×10−4) during an IVGTT. Among elderly
twins, G allele carriers had higher basal hepatic glucose
production (p=0.04). Finally, the G allele associated with the
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risk of having IFG (OR 1.26, 95% CI 1.08–1.47, p=0.002),
but not with IGT (OR 0.94, 95% CI 0.82–1.08, p=0.4) or
type 2 diabetes (OR 0.93, 95% CI 0.84–1.04, p=0.2).
Conclusions/interpretation The common rs560887 G allele
in the G6PC2/ABCB11 locus is associated with increased
fasting glycaemia and increased risk of IFG, associations
that may be partly related to an increased basal hepatic
glucose production rate.
Keywords ABCB11 . Association study .G6PC2 .
Genetic variants . Glucose production . Hepatic .
Insulin release . Type 2 diabetes
Abbreviations
IFG Impaired fasting glycaemia
IGRP Islet-specific glucose-6-phosphatase-related
peptide
IGT Impaired glucose tolerance
LD Linkage disequilibrium
SDC Steno Diabetes Center
Introduction
In humans the concentration of fasting plasma glucose is
subject to tight homeostatic control: a mechanism directed
by both neural and humoral factors. A few genetic variants
have been reported to influence plasma glucose levels in the
general population including GCK rs1799884 [1, 2], GCKR
rs780094 [3] and variants in the MTNR1B locus [4–6];
however, these variants explain only a minor part of the
total inter-individual variation in plasma glucose levels.
In a meta-analysis of two genome-wide association
studies totalling 5,088 non-diabetic individuals a significant
association between the rs563694 A allele in the G6PC2/
ABCB11 locus and elevated fasting plasma glucose was
reported (p=4×10−7). This finding was substantiated in a
large-scale replication study involving 23,524 non-diabetic
white individuals (p=7×10−26) [7] showing an effect size
of 0.065 mmol/l per A allele. A total of 5,734 individuals
from the Danish population-based Inter99 cohort genotyped
for rs563694 [7–9] was included in the study. Additional
analyses of the locus harbouring rs563694 revealed an even
stronger association of rs560887 (p=3×10−10) and
rs853789 (p=1×10−9) with fasting plasma glucose levels
in the initial sample of 5,088 non-diabetic individuals from
Finland and Sardinia [7]. Another study including 9,353
French individuals demonstrated that rs560887 was strong-
ly associated with fasting plasma glucose with an effect size
of 0.06 mmol/l per G allele (p=4×10−23) [10].
rs560887 is located within the third intron of the
glucose-6-phosphatase catalytic subunit 2 gene (G6PC2)
and is in strong linkage disequilibrium (LD) (r2>0.8) with
rs563694 located 10.9 kb away from rs560887 downstream
of G6PC2 [7], and with rs853789 located in intron 19 of
the ATP-binding cassette, sub-family B, member 11 gene
(ABCB11) 38.3 kb from rs560887 and 27.4 kb from
rs563694 (r2>0.8) [7].
Although the association of the G6PC2/ABCB11 variants
with fasting plasma glucose has been demonstrated, more
detailed physiological studies are lacking. The aim of the
present study was to evaluate the impact of rs560887 on
plasma glucose and serum insulin levels following oral or
i.v. glucose loads and to measure hepatic glucose produc-
tion both in the basal state and during hyperinsulinaemia.
Furthermore, we examined the effect of the variants on the
risk of having impaired fasting glycaemia (IFG), impaired
glucose tolerance (IGT) and type 2 diabetes. In addition,
potential associations with components of the metabolic
syndrome were examined.
Methods
Participants Details of the study populations are given in
Electronic supplementary material (ESM) Table 1. Partic-
ipants from the population-based Inter99 cohort (Clinical-
Trials.gov ID no: NCT00289237) [8, 9] involving 4,407
glucose-tolerant individuals who were characterised by an
OGTT were investigated for association between the
rs560887 genotype and quantitative metabolic traits.
Studies of insulin release after an i.v. glucose load (0.3 g
glucose/kg body weight) were performed in 366 individuals
with normal fasting glucose levels from a population-based
sample of young, healthy Danes recruited at the Research
Centre for Prevention and Health, Glostrup, Denmark [11]
and in a sample of 196 glucose-tolerant relatives of Danish
type 2 diabetic patients recruited at the Steno Diabetes
Center, Gentofte, Denmark (SDC) [12]. Additionally,
rs560887 was examined in a sample of 53 elderly and
106 young twins with normal glucose tolerance subjected
to a 2 h hyperinsulinaemic–euglycaemic clamp (40 mU m−2
min−1) with measures of hepatic glucose production during
the fasting state and upon insulin infusion [13].
The case–control studies of impaired glucose regulation
involving rs560887 included unrelated individuals with
isolated IFG recruited from the Inter99 cohort (n=486) and
at SDC (n=22), isolated IGT (Inter99 n=466, SDC n=64),
both IFG and IGT (Inter99 n=199, SDC n=16), type 2
diabetes (Inter99 n=323, SDC n=1,640), and glucose-
tolerant control individuals (Inter99 n=4,407, SDC
n=506). All control participants had normal fasting
glycaemia and were glucose-tolerant following an OGTT.
Diabetes, IFG and IGT were defined in accordance with
World Health Organization 1999 criteria [14].
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All participants from the Inter99 cohort (including patients
with treated type 2 diabetes) involving a total of 5,899
middle-aged individuals were evaluated in a case–control
study examining the association between the rs560887
genotype and the WHO-defined metabolic syndrome
(n=1,326) [14]. In the latter study, those having no
components of the metabolic syndrome were considered
as control individuals (n=1,702). More detailed description
of participants, biochemical assays and anthropometrical
measurements are given in the ESM.
All participants were of Danish nationality and informed
written consent was obtained from all individuals before
participation. The studies were approved by the Ethical
Committee of Copenhagen and were in accordance with the
principles of the Helsinki Declaration II.
Biochemical and anthropometric measures The plasma
glucose and serum insulin concentrations were measured
as described in the ESM.
Genotyping Genotyping of rs560887 was performed using
TaqMan allelic discrimination (KBioscience, Hoddesdon,
UK). Genotype data were obtained in more than 97% of
the DNA samples, and among 459 duplicate pairs no
discrepancies were found. All genotype groups obeyed
Hardy–Weinberg equilibrium.
Statistical analysis Logistic regression analysis and Fish-
er’s exact test were applied to test for differences in
genotype distribution or allele frequencies. A general linear
model was applied to test quantitative variables for differ-
ences between genotype groups assuming an additive
model. Assuming an allele frequency of the rs560887 A
allele of 30% our study of quantitative traits in the Inter99
sample (n=4,407) has a power of 58%, 93% and 99% to
detect a genotype effect difference of 5%, 8% and 10% of
an SD, respectively, considering an α of 5%. In the cohort
of young, healthy Danes (n=366) we have a power of 9%,
17% and 22% to detect a genotype effect difference of 5%,
8% and 10% of an SD. Power for the quantitative traits was
estimated using simulations assuming an additive genetic
model both for the simulation of the data and for testing the
data using a linear model. The empirical variance of the
observed traits was used to simulate phenotypes from a
normal distribution so that variance across genotypes was
drawn from the estimated variance. The statistical analyses
were performed using RGui version 2.6.1 (available at
www.r-project.org, accessed 28 May 2009). Analyses in the
sample of non-diabetic relatives of Danish type 2 diabetic
patients were performed applying a mixed model including
the family relationship (coded as a family number) as a
random factor, the genotype and sex as fixed factors, and
age and BMI as covariates using the Statistical Package for
Social Sciences (SPSS, Chicago, IL, USA) version 14.0.
Analyses of hepatic glucose production in the sample of
young and elderly twins were calculated using the SAS
system version 8.2 (Cary, NC, USA) applying a mixed
model including a random-effect term for twin pair
membership and a fixed-effects term for zygosity. p<0.05
was considered significant.
Results
The impact of rs560887 on OGTT-derived diabetes-related
quantitative traits was evaluated in a population-based
sample of glucose-tolerant individuals from the Inter99
cohort (n=4,407) (Table 1). The rs560887 G allele was
associated with elevated fasting plasma glucose (p=2×
10−14), as well as elevated levels of serum insulin (p=1×
10−4), 30 min after an oral glucose load and with increased
AUC for serum insulin (p=0.003) during an OGTT,
applying an additive genetic model adjusting for age, sex
and BMI. Furthermore, the rs560887 G allele was associ-
ated with an increased glucose-stimulated insulin release as
assessed by the insulinogenic index (p=3×10−6). The same
genotype was not associated with 30 or 120 min plasma
glucose levels following an OGTT. The insulin concen-
trations at each time point during the OGTT (0, 30 and
120 min) were additionally analysed adjusting for age, sex,
BMI and the simultaneous or fasting plasma glucose
concentration; however, the results remained the same
when compared with the insulin data adjusted for age, sex
and BMI alone (data not shown).
In a subsequent analysis of rs560887 in a population-
based sample of 366 young, healthy glucose-tolerant Danes
based on normal fasting glucose according to the WHO
criteria [14], we found a tendency towards increased acute
serum insulin response during an i.v. glucose load (p=0.09)
for carriers of the G allele (Table 2). These findings were
substantiated in a study of 196 glucose-tolerant relatives of
Danish type 2 diabetic patients. Here we observed a
significant association of rs560887 G allele carriers with
increased acute serum insulin response following an i.v.
glucose load (p=4×10−4; Table 2). The results remained
unchanged when adjusting the acute serum insulin response
for fasting plasma glucose.
To further investigate the effect of rs560887 on hepatic
glucose production we examined a group of 53 elderly and
106 young glucose-tolerant twins all subjected to a 2 h
hyperinsulinaemic–euglycaemic clamp. Among the elderly
twins, G allele carriers had a higher basal hepatic glucose
production (p=0.04), whereas no effect of genotype was
seen on hepatic glucose production (p=0.5) or insulin-
stimulated glucose disposal rate (p=1.0) during the clamp
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Table 1 Quantitative metabolic traits in the population-based Inter99 cohort including 4,407 glucose-tolerant middle-aged individuals stratified
according to rs560887 genotype
Variable GG GA AA p value
N 2,133 1,870 404
Men/women 996/1,137 853/1,017 197/207
Age (years) 45±8 45±8 45±8
BMI (kg/m2) 25.5±4.0 25.5±4.1 25.4±4.1 0.8
Plasma glucose
Fasting (mmol/l) 5.35±0.39 5.28±0.40 5.22±0.43 2×10−14
30 min post-OGTT (mmol/l) 8.18±1.54 8.18±1.50 8.2±1.63 0.9
120 min post-OGTT (mmol/l) 5.49±1.12 5.54±1.12 5.43±1.12 0.9
OGTT AUC (mmol/l×min) 176±101 185±99 189±106 0.002
Serum insulin
Fasting (pmol/l) 32 (23–46) 31 (23–46) 33 (23–49) 0.5
30 min post-OGTT (pmol/l) 253 (181.5–358) 240 (176–337) 229 (162–322) 1×10−4
120 min post-OGTT (pmol/l) 137 (86–211) 140 (92–209) 140 (89–229) 0.1
OGTT AUC (pmol/l×min) 18,150 (13,118–25,560) 17,318 (12,401–24,780) 16,965 (11,670–24,150) 0.003
HOMA-IR 1.3±0.8 1.3±0.8 1.3±0.9 0.7
Insulinogenic index (pmol×pmol−1) 27.08 (18.73–39.82) 25.24 (17.82–37.06) 23.72 (17.23–34.1) 3×10−6
Data on plasma glucose and HOMA-IR are means±SD, whereas data on serum insulin and insulinogenic index are medians and interquartile
ranges
Insulinogenic index was calculated as (serum insulin at 30 min [pmol/l]-fasting serum insulin [pmol/l])/plasma glucose at 30 min (mmol/l).
Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as fasting plasma glucose (mmol/l) multiplied by fasting serum
insulin (mU/l) and divided by 22.5
Values of plasma glucose, serum insulin, HOMA-IR and insulinogenic index were log transformed before statistical analysis
Calculated p values were adjusted for age, sex and BMI (where appropriate) assuming an additive model
Table 2 Acute serum insulin response in young, healthy Danes and non-diabetic relatives of Danish type 2 diabetic patients subjected to an
IVGTT
Variable GG GA AA p value
Young, healthy Danes (n=366)
n (men/women) 181 (96/85) 152 (66/86) 33 (15/18)
Age (years) 25±3 25±4 26±4
BMI (kg/m2) 23.4±3.7 23.6±3 9 23.3±3.4 0.7
Acute serum insulin response 0–8 min (pmol/l×min) 2,417±1,760 2,152±1,433 2,160±1,341 0.09
Non-diabetic relatives of Danish type 2 diabetic patients
(n=196)
n (men/women) 77 (37/40) 95 (44/51) 24 (7/17)
Age (years) 39±9 39±8 39±10
BMI (kg/m2) 25.2±4.4 25.7±4.2 25.3±4.2 0.7
Acute serum insulin response 0−8 min (pmol/l×min) 3,046±2,162 1,918±1,292 1,817±1,240 4×10−4
Data are means±SD
All 366 young, healthy Danes had normal fasting glucose levels according to 1999 WHO criteria [14]. The 196 non-diabetic relatives of Danish
type 2 diabetic patients all had normal glucose tolerance status following an OGTT
Acute serum insulin response 0–8 min was calculated as the incremental AUC during the IVGTT by the trapezoidal method
Calculated p values were adjusted for age, sex and BMI (where appropriate) among young, healthy Danes or age, sex, BMI (where appropriate)
and family relationship among relatives of type 2 diabetes patients
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(Table 3). In the group of young twins (Table 3), and when
combining data from young and elderly twins, we found no
genotype effect on hepatic glucose production.
The risk of having IFG was evaluated in a case–
control study of 508 individuals with IFG and 4,913
glucose-tolerant control individuals. With an OR of 1.26
(95% CI 1.09–1.47) the rs560887 G allele associates
with an increased risk of having isolated IFG (p=0.002)
(Table 4). On the contrary, the rs560887 G allele was not
associated with the risk of having isolated IGT (OR 0.94,
95% CI 0.82–1.08, p=0.4) or type 2 diabetes (OR 0.93,
95% CI 0.84–1.04, p=0.2). However, the rs560887
G allele associates with an increased risk of having
combined IFG and IGT (OR 1.40, 95% CI 1.11–1.76,
p=0.005) (Table 4).
Potential associations of the rs560887 G allele with
components of the WHO-defined metabolic syndrome were
evaluated in a case–control study involving all participants
from the Inter99 cohort (n=5,881). We found no associa-
tion of the rs560887 G allele with the risk of having either
the metabolic syndrome (OR 1.01, 95% CI 0.89–1.15,
p=0.9) or any components of the metabolic syndrome
(ESM Table 2).
Discussion
In the present study we show that even though the G allele
of rs560887 associates with increased fasting plasma
glucose, the G allele is not implicated in altered plasma
glucose levels during an OGTT. Furthermore, the G allele
associates with increased insulin release after both an oral
glucose load and an i.v. glucose injection. Interestingly, the
G allele shows nominal association with elevated basal
hepatic glucose production in elderly twins. Also, we show
that the variant associates with IFG, but not with IGT, type
2 diabetes, or any component of the 1999 WHO-defined
metabolic syndrome.
The human G6PC2 encodes the islet-specific glucose-
6-phosphatase-related peptide (IGRP). IGRP is known to
be specifically expressed in pancreatic beta cells in
humans [15], and although no catalytic activity has been
reported for IGRP [15–19] it may be assumed that IGRP
dephosphorylates glucose 6-phosphate to form glucose,
opposing the action of glucokinase, the glucose sensor of
the beta cell. Therefore, the effect of variants in the
G6PC2/ABCB11 locus on fasting plasma glucose may, as
suggested by previous reports [7, 10], imply that the
rs560887 G allele results in an increased expression or
higher functional activity of IGRP, hereby decreasing the
glucose flux into the glycolytic pathway directing the
pancreatic beta cell to a higher glucostatic set-point and
thus upregulating the impact of the concentration of
plasma glucose on insulin secretion in the fasting state
[7, 10]. These findings and interpretations are in accord
with observations in the G6pc2 knockout mice, where lack
of G6pc2 results in a decreased fasting blood glucose
concentration [20]. Moreover, a French functional study
reported that the G allele of rs573225, a variant in high
LD with rs560887, associates with higher promoter
activity, suggesting a higher expression of G6PC2 and
thereby IGRP [21]. If the rs560887 G allele or another
Variable GG GA AA p value
Young twins (n=106)
n (men/women) 54 (31/23) 45 (23/22) 7 (4/3)
Age (years) 28±2 28±2 28±1
BMI (kg/m2) 23.9±3.0 24.1±3.4 24.9±1.5 0.5
Basal (mg kg−1 min−1)
Hepatic glucose production 3.06±0.57 3.10±0.52 2.92±0.19 0.8
Clamp (mg kg−1 min−1)
Hepatic glucose production 1.45±0.45 1.55±0.46 1.40±0.30 0.7
Glucose disposal rate 11.9±3.1 12.0±3.2 10.3±4.4 0.5
Elderly twins (n=53)
n (men/women) 22 (8/14) 20 (7/13) 11 (8/3)
Age (years) 62±2 62±3 62±2
BMI (kg/m2) 26.2±3.8 24.3±4.2 27.4±4.9 0.8
Basal (mg kg−1 min−1)
Hepatic glucose production 3.2±0.4 3.1±0.4 2.8±0.4 0.04
Clamp (mg kg−1 min−1)
Hepatic glucose production 1.5±0.8 1.9±0.7 1.7±0.8 0.5
Glucose disposal rate 19.5±3.0 11.7±2.8 10.4±3.0 1.0
Table 3 Metabolic rates in
young twins and elderly
glucose-tolerant twins stratified
according to rs560887 genotype
Data are means±SD
p values were calculated apply-
ing a mixed model including a
random-effect term for twin pair
membership and a fixed-effects
term for zygosity applying an
additive genetic model adjusted
for age, sex and percentage
body fat
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variant in high LD increases the IGRP activity in the beta
cell it would most likely lead to elevated plasma glucose
levels during an OGTT as a result of a relatively decreased
glucose-stimulated serum insulin release. However, we
found normal plasma glucose levels and elevated serum
insulin levels 30 min after oral and i.v. glucose loads.
Thus, our data does not support a sole IGRP-mediated
effect of rs560887 on plasma glucose levels.
rs560887 is in high LD with rs853787 and rs853789
located within ABCB11. ABCB11 encodes the bile salt
export pump (BSEP), which is evolutionarily highly
conserved and solely expressed in the liver. BSEP is
involved in the ATP-dependent secretion of bile salts in
the hepatocytes and the protein has been linked to inherited
forms of cholestasis, resulting in diverse hepato-
pathological phenotypes [22]. Variation in ABCB11 impairs
bile acid secretion [23–25], and studies involving bile acid
sequestrants have shown association between interruption
of bile acid re-absorption and decreased levels of plasma
glucose and improved insulin sensitivity, most probably as
a result of lowered serum triacyglycerol levels [26].
Interestingly, although exploratory because of the low
number of individuals in the cohort, it seems from the
present study of elderly twins that the increase in fasting
plasma glucose in carriers of the rs560887 G allele may be
explained by an increase in glucose production from the
liver. This finding could, however, not be replicated in the
group of young twins and may in theory be explained by an
age-dependency in the expression of this distinct pheno-
typic trait. If the elevated basal hepatic glucose production
in G allele carriers is a true finding, it might imply that the
raised insulin levels after both oral and i.v. glucose
challenges are a compensatory beta cell response primed
by the increased fasting plasma glucose concentrations. An
interesting approach to further evaluate the ABCB11 locus
would be to examine rs560887 in relation to concentrations
of bile acid; however, these data are not available in the
present study. Given the complex pattern of association we
cannot exclude the possibility that two independent signals
of association exist, which influence both the function of
G6PC2 in the beta cell and ABCB11 in the liver. Functional
studies and/or further fine mapping of the locus will be
necessary to identify the actual causal variant and the exact
mechanisms leading to elevated fasting plasma glucose
levels.
Interestingly, even though the rs560887 G allele asso-
ciates strongly with fasting plasma glucose and IFG it is not
associated with IGT or overt type 2 diabetes in the present
study. A recent large-scale study of loci affecting fasting
plasma glucose levels reported a significant protective
effect of the rs560887 G allele on type 2 diabetes (OR
0.93, 5% CI 0.89–0.97, p=0.0017) [6] with a similar effect
size to that observed in the present study. Combined, these
studies strongly indicate that the rs560887 G allele
associates with elevated fasting plasma glucose levels, and
a decreased risk of type 2 diabetes, probably via a hyper-
response of the beta cell to postprandial elevation in
circulating glucose levels.
A progressive relationship between elevated plasma
glucose levels and increased cardiovascular risk, which
extends below the threshold chosen for diabetes, has been
demonstrated [27]. We have previously shown that the
GCK rs1799884 A allele associates with both fasting and
post-OGTT plasma glucose levels and with different
Table 4 Genotype distribution and allele frequency of rs560887 among patients with type 2 diabetes, individuals with isolated IFG, isolated IGT
or both IFG and IGT, and glucose-tolerant control individuals
Glucose-tolerant
(n=4,913)
Isolated IFG
(n=508)
Isolated IGT
(n=530)
IFG and IGT
(n=215)
Type 2 diabetes
(n=1,963)
GG, n (%) 2,360 (48) 277 (54) 245 (46) 124 (58) 893 (46)
GA, n (%) 2,098 (43) 197 (39) 230 (44) 77 (36) 867 (44)
AA, n (%) 455 (9) 34 (7) 55 (10) 14 (6) 203 (10)
G allele frequency, % (95% CI) 69.4 (68.5–70.3) 73.9 (71.1–76.6) 67.9 (65.0–70.7) 75.6 (71.2–79.6) 67.5 (66.0–69.0)
Unadjusted additive model OR (95% CI) – 1.25 (1.08–1.45) 0.93 (0.81–1.07) 1.36 (1.09–1.72) 0.92 (0.85–0.99)
p valuea – 0.003 0.3 0.006 0.04
Adjusted additive model OR (95% CI) – 1.26 (1.09–1.47) 0.94 (0.82–1.08) 1.40 (1.11–1.76) 0.93 (0.84–1.04)
p valueb – 0.002 0.4 0.005 0.2
Data are numbers of individuals with each genotype (% of each group)
Patients with type 2 diabetes were recruited at the SDC (n=1,640) and from the population-based Inter99 cohort [8, 9] (n=323), with isolated IFG
(SDC=22, Inter99=486), isolated IGT (SDC=64, Inter99=466), and both IFG and IGT (SDC=16, Inter99=199). Glucose-tolerant individuals
were recruited from population-based studies at SDC (n=506) and the Inter99 cohort (n=4,407)
a Unadjusted differences in G allele frequencies were calculated using Fisher’s exact test
b The p values compare G allele distributions between type 2 diabetes cases, participants with IFG, IGT, or both IFG and IGT with glucose-
tolerant control individuals applying an additive logistic regression model, while adjusting for age, sex and BMI
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components of the metabolic syndrome [1]. However, we
find no association of the rs560887 G allele with any
components of the metabolic syndrome. This might be
because of the lack of association with elevated glucose
levels after an oral glucose load or the low number of
individuals in the sub-analyses.
In conclusion, the present study reports evidence that
the observed association of the common rs560887 G
allele in the G6PC2/ABCB11 locus with increased fasting
plasma glucose and IFG may be related to increased
hepatic glucose production rather than a pancreatic beta
cell dysfunction. Furthermore, even though the rs560887
G allele is strongly associated with elevated fasting
plasma glucose and glucose-stimulated serum insulin
release, the variant is not involved in the inter-individual
variation of glucose levels after an oral glucose load or the
risk of having the metabolic syndrome among middle-
aged Danes.
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